Science Featured on MSN1mon
This Common Cancer Treatment Might Help Patients Stay Healthier for LongerUnderstanding how to keep leukemia in remission for longer in older patients remains a significant challenge in cancer ...
If you are worried about using this medicine, speak to your doctor or pharmacist. Azacitidine-Teva contains the active ingredient azacitidine. Azacitidine-Teva is used to treat myelodysplastic ...
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...
11d
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...
Zacks.com on MSN4mon
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalThe phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed ...
EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized ...
Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s ...
In total, 9 of 10 frontline patients across two trials achieved remission* when receiving the triplet combination of mipletamig + venetoclax + azacitidine (ven/aza). Notably, no CRS has been reported ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback